Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
HALO
STRONG BUYFLAGHalozyme Therapeutics, Inc. · Healthcare · United States · $9.7B · Avg Vol: $151M/d
Halozyme has quality Q74 and strong momentum M77, but value at V36 is well below the calibrated floor, so stage one fails. Insider selling of 0.10% is separately adverse.
COMPANY DESCRIPTION
Halozyme Therapeutics, Inc. is a biotechnology company focused on its proprietary ENHANZE® drug delivery technology, utilizing recombinant human hyaluronidase enzyme (rHuPH20). This innovative platform facilitates subcutaneous administration of biologics, thereby improving patient convenience and reducing healthcare costs. Halozyme operates primarily through a high-margin licensing model, partnering with major pharmaceutical companies to enhance the delivery of their blockbuster therapeutics.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 660.1M | 829.3M | 1.0B | 1.4B | 28.4% | 1.5B | 1.8B | 2.0B | 19.8% |
| EPS | 1.48 | 2.13 | 3.50 | 2.64 | 21.3% | 2.82 | — | — | — |
| Shares | 135.2M | 126.8M | 123.1M | 117.8M | -12.9% | 118.6M | — | — | — |
| Debt | 1.5B | 1.5B | 1.5B | 2.1B | 12.5% | 2.2B | — | — | — |
| Equity | 169.8M | 83.8M | 363.8M | 48.8M | -34.0% | — | — | — | — |
| Op CF | 240.1M | 388.6M | 479.1M | 651.6M | 39.5% | 677.4M | — | — | — |
| Inv CF | -487.0M | -96.9M | -262.7M | -545.8M | — | — | — | — | — |
| Fin CF | 362.4M | -408.0M | -218.9M | -85.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HALO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HALO | Halozyme Therapeutics, Inc.(you) | $9.7B | 93 | STRONG BUY |
| TGTX | TG Therapeutics, Inc. | $8.6B | 85 | STRONG BUY |
| EXEL | Exelixis, Inc. | $13.9B | 97 | STRONG BUY |
| CORT | Corcept Therapeutics Incorporated | $10.2B | 79 | BUY |
| INCY | Incyte Corporation | $23.5B | 96 | STRONG BUY |
| KRYS | Krystal Biotech, Inc. | $9.9B | 72 | BUY |
| 0K6R.L | Neurocrine Biosciences, Inc. | $16.9B | 80 | BUY |
| BMRN | BioMarin Pharmaceutical Inc. | $11.5B | 72 | BUY |
| CPRX | Catalyst Pharmaceuticals, Inc. | $3.9B | 99 | STRONG BUY |
| LGND | Ligand Pharmaceuticals Incorporated | $6.0B | 75 | BUY |
Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.5%